The California Institute of Technology has received US Patent No. 7,601,270, "Microfabricated elastomeric valve and pump systems." The patent claims a method of fabricating an elastomeric structure by: a) forming an elastomeric layer on top of a micromachined mold; b) forming a second elastomeric layer on top of a second micromachined mold; c) bonding the bottom surface of the second elastomeric layer onto the top surface of the first elastomeric layer so that a control channel forms in the second recess between the first and second elastomeric layers; and d) positioning the first elastomeric layer on top of a planar substrate such that a flow channel forms in the first recess between the first elastomeric layer and the planar substrate.
Nanogen of San Diego has received US Patent No. 7,601,493, "Methods and apparatus for screening and detecting multiple genetic mutations." An assay system and methods are described where patient samples containing genomic DNA are analyzed for the presence of known genetic polymorphisms using a universal-reporter strategy. In a one embodiment, the amplified DNA is localized at test sites in an array of sites on a microchip followed by a series of hybridization reactions that screen for the presence of a single mutation from among a number of mutations, and allow the identification of specific mutations. In addition to universal reporters, the assay may use blockers and discriminators for screening and identification of known polymorphisms, according to the patent.
Hisamitsu Pharmaceutical of Tosu, Japan, and NGK Insulators of Nagoya, Japan, have received US Patent No. 7,601,532, "Microarray for predicting the prognosis of neuroblastoma and method for predicting the prognosis of neuroblastoma." The patent claims a microarray for predicting the prognosis of neuroblastoma, where the microarray has 25 to 45 probes related to good prognosis, which are hybridized to a gene transcript whose expression is increased in a good prognosis patient with neuroblastoma and are selected from 96 polynucleotides consisting of nucleotide sequences provided in the patent. The described array also has 25 to 45 probes related to poor prognosis, which are hybridized to a gene transcript whose expression is increased in a poor prognosis patient with neuroblastoma and are selected from 104 polynucleotides consisting of different nucleotide sequences named in the patent.
Illumina has received US Patent No. 7,602,952, "Scanner having spatial light modulator." The patent describes the incorporation of an adaptive spectral filter into a confocal scanner optical arrangement or other suitable optical device in order to permit real-time control of the fluorescence signal spectrum being monitored. This new arrangement would allow for better balancing of the fluorescence signals in the analysis of the array, the inventors state in the patent.